SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2015
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS On February 5, 2016, we announced that we had entered into the First Amendment with Endo Global Ventures to amend certain provisions of the License Agreement. The License Agreement was previously filed with the SEC on September 1, 2011 as Exhibit 10.1 to a Current Report on Form 8-K. The First Amendment has an effective date of January 1, 2016. Pursuant to the First Amendment, the Company and Endo Global Ventures mutually agreed that in exchange for an $8.25 million lump sum payment by Endo Global Ventures to the Company, Endo Global Ventures is no longer required to pay an additional mark-up of cost of goods to the Company for sales by non-affiliated sublicensees of Endo Global Ventures outside of the U.S.; provided, however, that Endo Global Ventures will still be required to pay a mark-up on cost of goods for sales made in the “Endo Territory”, which will always include sales made in the U.S. and sales made in any other country where Endo Global Ventures sells the product directly or through affiliated sublicensees. The $8.25 million lump sum payment was due by February 11, 2016 and has been paid. The Company will recognize the income resulting from the $8.25 million dollar payment over time based on sales by non-affiliated sublicensees of Endo Global Ventures outside of the U.S. In addition, pursuant to the First Amendment, the Company and Endo Global Ventures agreed that Endo Global Ventures may opt-in early to indications, prior to the Company’s submission of a clinical trial report, with the Company’s consent, such consent not to be unreasonably withheld. Endo Global Ventures previously opted-in early, with the consent of the Company, in the case of lateral hip fat and plantar fibromatosis, as documented by a Current Report on Form 8-K filed with the SEC on November 6, 2015. For early opt-ins, Endo Global Ventures will be required to make an opt-in payment of $0.5 million on a per indication basis. For regular opt-ins, Endo Global Ventures will be required to make an opt-in payment on a per indication basis, following the submission of a clinical trial report. A redacted version of the First Amendment was filed with the SEC as Exhibit 10.1 to Current Report on Form 8-K on February 5, 2016.

13. SUBSEQUENT EVENTS

On February 5, 2016, we announced that we had entered into the First Amendment with Endo Global Ventures to amend certain provisions of the License Agreement. The License Agreement was previously filed with the SEC on September 1, 2011 as Exhibit 10.1 to a Current Report on Form 8-K.

The First Amendment has an effective date of January 1, 2016. Pursuant to the First Amendment, the Company and Endo Global Ventures mutually agreed that in exchange for an $8.25 million lump sum payment by Endo Global Ventures to the Company, Endo Global Ventures is no longer required to pay an additional mark-up of cost of goods to the Company for sales by non-affiliated sublicensees of Endo Global Ventures outside of the U.S.; provided, however, that Endo Global Ventures will still be required to pay a mark-up on cost of goods for sales made in the “Endo Territory”, which will always include sales made in the U.S. and sales made in any other country where Endo Global Ventures sells the product directly or through affiliated sublicensees. The $8.25 million lump sum payment was due by February 11, 2016 and has been paid. The Company will recognize the income resulting from the $8.25 million dollar payment over time based on sales by non-affiliated sublicensees of Endo Global Ventures outside of the U.S.

In addition, pursuant to the First Amendment, the Company and Endo Global Ventures agreed that Endo Global Ventures may opt-in early to indications, prior to the Company’s submission of a clinical trial report, with the Company’s consent, such consent not to be unreasonably withheld. Endo Global Ventures previously opted-in early, with the consent of the Company, in the case of lateral hip fat and plantar fibromatosis, as documented by a Current Report on Form 8-K filed with the SEC on November 6, 2015. For early opt-ins, Endo Global Ventures will be required to make an opt-in payment of $0.5 million on a per indication basis. For regular opt-ins, Endo Global Ventures will be required to make an opt-in payment on a per indication basis, following the submission of a clinical trial report. A redacted version of the First Amendment was filed with the SEC as Exhibit 10.1 to Current Report on Form 8-K on February 5, 2016.